metally.net

Metal News


Home > News > Simeprevir Administered Once Daily Demonstrates Sustained Virologic...

Simeprevir Administered Once Daily Demonstrates Sustained Virologic...



Print Back Archive

Janssen R&D Ireland have announced primary efficacy and safety results from two global Phase 3 studies demonstrating that use of the investigational protease inhibitor simeprevir led to sustained virologic response 12 weeks after the end of treatment in 80 and 81 percent, respectively, of treatment-naive genotype 1 chronic hepatitis C adult ... (more)




Click Here to read the entire article...


Music News Archive

Copyright 2005 Metally.net | Privacy Policy | Contact Us | Site Map | Search